Loading...
•
Sep 30, 2023
Enanta Pharmaceuticals Q4 2023 Earnings Report
Enanta Pharmaceuticals reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
Key Takeaways
Enanta Pharmaceuticals reported a revenue of $18.9 million for the quarter ended September 30, 2023, compared to $20.3 million for the same period in 2022. The net loss for the quarter was $28.1 million, or $1.33 per diluted common share, compared to a net loss of $26.3 million, or $1.27 per diluted common share, for the corresponding period in 2022. Cash, cash equivalents, and marketable securities totaled $370.0 million at September 30, 2023.
Initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024
Streamlined Business and Significantly Lowered 2024 R&D and G&A Spending Guidance to Support Ongoing Operations
Cash and Marketable Securities Totaled $370 Million at September 30, 2023
Advancing RSVPEDs and RSVHR, ongoing Phase 2 trials of EDP-938, with a data readout from at least one of these studies in the third quarter of 2024.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Forward Guidance
Enanta expects that its current cash, cash equivalents and short-term marketable securities, as well as its continuing retained portion of royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs through fiscal 2027.